The recombinant antibody HBsAg-Fab of hepatitis B virus to block hepatitis B reinfection after liver transplantation: a research in vitro
Author:
Affiliation:

Clc Number:

R 617; R 341.1

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Abstract:Objective:To study the effect of recombinant antibody HBsAg-Fab of hepatitis B virus (HBV) to block hepatitis B reinfection after liver transplantation.
    Methods:The functional efficiency of antibody Fab in blocking hepatitis B reinfection after LT was analysis and studied by vitro infection test, complement toxicity assay and virus infection test, calculated the antibody absorption rate and cell death rate and cell infection rate,
    Results:When the group with and the group without recombinant antibody Fab were compared, the antibody absorption rate, cell death rate and cell infection rate between the 2 groups showed sigificant defference (P<0.05). The tese data had significant statistical defference.
    Conclusions:Recombinant antibody Fab can block antibody absorption by the target cell, can induce complement-dependent toxic death and damage of target cells, and decrease the HBV infection rate of primary human hepatocytes. The in vitro efficacy test of recombinant gene antibody Fab can be a basis for its use clinically in vivo.

    Reference
    Related
    Cited by
Get Citation

PAN Tao, TANG Li, CHEN Zhi-Shui, WANG Da-wei, CHENG Dun-xiu, GUO Hui.The recombinant antibody HBsAg-Fab of hepatitis B virus to block hepatitis B reinfection after liver transplantation: a research in vitro [J]. Chin J Gen Surg,2007,16(8):10-.
DOI:10.7659/j. issn.1005-6947.2007.08.810

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:January 01,1900
  • Revised:January 01,1900
  • Adopted:
  • Online: August 25,2007
  • Published: